Free Trial

Nuvectis Pharma (NVCT) Competitors

Nuvectis Pharma logo
$6.41
-1.06 (-14.19%)
(As of 11/1/2024 ET)

NVCT vs. EXAI, NUVB, TNGX, CRMD, NGNE, QTTB, AVXL, CRVS, LRMR, and ALMS

Should you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Exscientia (EXAI), Nuvation Bio (NUVB), Tango Therapeutics (TNGX), CorMedix (CRMD), Neurogene (NGNE), Q32 Bio (QTTB), Anavex Life Sciences (AVXL), Corvus Pharmaceuticals (CRVS), Larimar Therapeutics (LRMR), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry.

Nuvectis Pharma vs.

Nuvectis Pharma (NASDAQ:NVCT) and Exscientia (NASDAQ:EXAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Exscientia received 2 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 90.00% of users gave Nuvectis Pharma an outperform vote while only 37.93% of users gave Exscientia an outperform vote.

CompanyUnderperformOutperform
Nuvectis PharmaOutperform Votes
9
90.00%
Underperform Votes
1
10.00%
ExscientiaOutperform Votes
11
37.93%
Underperform Votes
18
62.07%

Nuvectis Pharma currently has a consensus target price of $21.00, indicating a potential upside of 227.61%. Exscientia has a consensus target price of $7.00, indicating a potential upside of 42.86%. Given Nuvectis Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Nuvectis Pharma is more favorable than Exscientia.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvectis Pharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Exscientia
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Nuvectis Pharma has higher earnings, but lower revenue than Exscientia. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Exscientia, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvectis PharmaN/AN/A-$22.26M-$1.29-4.97
Exscientia$25.60M23.14-$181.56M-$1.30-3.77

In the previous week, Nuvectis Pharma had 1 more articles in the media than Exscientia. MarketBeat recorded 1 mentions for Nuvectis Pharma and 0 mentions for Exscientia. Nuvectis Pharma's average media sentiment score of 0.00 equaled Exscientia'saverage media sentiment score.

Company Overall Sentiment
Nuvectis Pharma Neutral
Exscientia Neutral

Nuvectis Pharma has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Exscientia has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 41.6% of Exscientia shares are held by institutional investors. 35.8% of Nuvectis Pharma shares are held by insiders. Comparatively, 16.4% of Exscientia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvectis Pharma has a net margin of 0.00% compared to Exscientia's net margin of -620.99%. Exscientia's return on equity of -37.56% beat Nuvectis Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvectis PharmaN/A -152.26% -106.23%
Exscientia -620.99%-37.56%-26.19%

Summary

Nuvectis Pharma beats Exscientia on 10 of the 16 factors compared between the two stocks.

Get Nuvectis Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVCT vs. The Competition

MetricNuvectis PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$119.55M$7.41B$5.48B$8.52B
Dividend YieldN/A7.92%5.07%4.13%
P/E Ratio-4.9712.34128.5016.14
Price / SalesN/A400.631,495.8497.42
Price / CashN/A47.4339.6734.18
Price / Book9.165.604.765.07
Net Income-$22.26M$153.56M$119.00M$225.46M
7 Day Performance-26.83%0.13%0.79%0.54%
1 Month Performance0.47%15.20%5.64%3.75%
1 Year Performance-32.24%41.11%36.71%29.48%

Nuvectis Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVCT
Nuvectis Pharma
1.8853 of 5 stars
$6.41
-14.2%
$21.00
+227.6%
-30.3%$119.55MN/A-4.978High Trading Volume
EXAI
Exscientia
1.4357 of 5 stars
$4.86
-5.3%
$7.00
+44.0%
-7.5%$587.51M$21.02M-3.74280Positive News
NUVB
Nuvation Bio
3.8286 of 5 stars
$2.22
-5.1%
$6.40
+188.9%
+98.3%$583.23MN/A-1.0560Upcoming Earnings
TNGX
Tango Therapeutics
2.7852 of 5 stars
$5.44
-4.9%
$15.14
+178.6%
-37.3%$582.33M$42.51M-4.7790
CRMD
CorMedix
2.7027 of 5 stars
$10.06
flat
$15.20
+51.2%
+193.8%$580.79M$806,119.00-10.8130Earnings Report
Analyst Forecast
News Coverage
High Trading Volume
NGNE
Neurogene
1.8004 of 5 stars
$44.01
+0.6%
$51.00
+15.9%
N/A$571.87M$925,000.000.0090
QTTB
Q32 Bio
1.9784 of 5 stars
$47.23
+2.0%
$72.33
+53.2%
N/A$569.59M$-6,651,000.00-2.0539News Coverage
AVXL
Anavex Life Sciences
3.4898 of 5 stars
$6.62
+15.9%
$40.00
+504.2%
+21.6%$560.33MN/A-13.2440News Coverage
High Trading Volume
CRVS
Corvus Pharmaceuticals
1.5954 of 5 stars
$8.84
+0.5%
$10.83
+22.5%
+671.2%$550.45MN/A-19.6430Upcoming Earnings
Analyst Downgrade
Short Interest ↑
LRMR
Larimar Therapeutics
2.8615 of 5 stars
$8.23
-2.8%
$20.43
+148.4%
+169.7%$539.80MN/A-7.1530Earnings Report
Analyst Forecast
News Coverage
ALMS
Alumis
N/A$11.32
+0.8%
$27.50
+142.9%
N/A$534.51MN/A0.00N/AAnalyst Forecast
News Coverage

Related Companies and Tools


This page (NASDAQ:NVCT) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners